SMTL ID : 5gjd.1

Crystal structure of human TAK1/TAB1 fusion protein in complex with ligand 2

Coordinates

PDB Format

Method

X-RAY DIFFRACTION 2.79 Å

Oligo State

monomer

Ligands

1 x 6V3: 1-(4-((1H-pyrrolo[2,3-b]pyridin-4-yl)oxy)phenyl)-3-(5-(4-methylpiperazin-1-yl)naphthalen-2-yl)urea(Non-covalent)

6V3.1: 20 residues within 4Å: Chain A: V.17, V.25, A.36, K.38, E.52, Q.55, L.56, I.64, V.65, M.79, E.80, Y.81, A.82, L.119, I.128, H.129, L.138, C.149, D.150, F.151 17 PLIP interactions: 17 interactions with chain A Hydrophobic interactions: A:V.25, A:A.36, A:K.38, A:E.52, A:L.56, A:I.64, A:L.119, A:L.138, A:D.150, A:F.151 Hydrogen bonds: A:E.52, A:E.52, A:Q.55, A:A.82, A:A.82, A:D.150 pi-Cation interactions: A:H.129

Links

RCSB   PDBe   PDBe-KB   PDBj   PDBsum   CATH   PLIP

Citation

Muraoka, T. et al., Development of a Method for Converting a TAK1 Type I Inhibitor into a Type II or c-Helix-Out Inhibitor by Structure-Based Drug Design (SBDD). Chem.Pharm.Bull. (2016)

Release Date

2016-11-16

Peptides

TAK1 kinase - TAB1 chimera fusion protein: A

SMTL:PDB

SMTL Chain Id:
PDB Chain Id:

A
A

TAK1 kinase - TAB1 chimera fusion protein

Related Entries With Identical Sequence